OncoCyte (OCX) Competitors

Cardio Diagnostics (NASDAQ:CDIO) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Does the media refer more to CDIO or OCX?

In the previous week, OncoCyte had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for OncoCyte and 5 mentions for Cardio Diagnostics. OncoCyte's average media sentiment score of 0.79 beat Cardio Diagnostics' score of 0.11 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OncoCyte	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer CDIO or OCX?

Cardio Diagnostics currently has a consensus price target of $1.35, indicating a potential upside of 59.42%. OncoCyte has a consensus price target of $4.06, indicating a potential upside of 40.57%. Given OncoCyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardio Diagnostics is more favorable than OncoCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
OncoCyte	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more volatility & risk, CDIO or OCX?

Cardio Diagnostics has a beta of 5.3, indicating that its stock price is 430% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Is CDIO or OCX more profitable?

Cardio Diagnostics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -1,890.62%. Cardio Diagnostics' return on equity of -96.30% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	N/A	-293.34%	-131.96%
OncoCyte	-1,890.62%	-96.30%	-41.12%

Which has stronger valuation & earnings, CDIO or OCX?

Cardio Diagnostics has higher earnings, but lower revenue than OncoCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$20K	914.12	-$8.38M	N/A	N/A
OncoCyte	$1.50M	15.93	-$27.78M	N/A	N/A

Do insiders and institutionals have more ownership in CDIO or OCX?

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 55.4% of OncoCyte shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 1.9% of OncoCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer CDIO or OCX?

OncoCyte received 3 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Cardio Diagnostics an outperform vote while only 7.94% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
Cardio Diagnostics	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%
OncoCyte	Outperform Votes 5 7.94%	Underperform Votes 58 92.06%

Summary

Cardio Diagnostics beats OncoCyte on 9 of the 15 factors compared between the two stocks.